Live
- Russia provided North Korea with anti-air missiles in exchange for troop deployment
- PCB appoints Azhar Ali as head of youth development
- Deepam-2 Scheme Reaches 5 Million Beneficiaries in Three Weeks, says Nadendla Manohar
- Will RG Kar tragedy impact Bengal bypoll results?
- BGT 2024:25: Josh Hazlewood picks four as Australia bundle out India for 150
- BRS rallies support for Lagacharla ‘victims’
- COP29: Scientists, artists, faith leaders call for greater commitment to delivery of climate finance
- Woman donates liver to husband, saves life
- Mechanic Rocky Review: Thrilling Action Film with Twists and Great Performances
- Ponguleti Sudhakar Reddy rubbishes Rahul Gandhi's claims on Modi and Adani
Government clears Johnson's single-dose Covid vaccine
Johnson & Johnson Covid-19 vaccine
India has granted Emergency Use Authorisation (EUA) to US drug maker Johnson & Johnson’s single-dose Covid-19 vaccine, Union Health Minister Mansukh Mandaviya said on Saturday.
New Delhi: India has granted Emergency Use Authorisation (EUA) to US drug maker Johnson & Johnson's single-dose Covid-19 vaccine, Union Health Minister Mansukh Mandaviya said on Saturday.
"Johnson and Johnson's single-dose Covid-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID-19," Mansukh Mandaviya said in a tweet. In a statement, Johnson & Johnson said this is an important step forward in accelerating the availability of their Covid-19 vaccine to help end the pandemic.
"We are pleased to announce that on August 7, 2021, the Government of India issued Emergency Use Authorisation (EUA) for the Johnson & Johnson Covid-19 single-dose vaccine in India, to prevent Covid-19 in individuals 18 years of age and older," Johnson & Johnson's India spokesperson said in a statement.
So far, four vaccines have been given Emergency Use Authorisation (EUA) in India - AstraZeneca's Covishield, Covaxin, Sputnik V and Moderna. On August 5, Johnson & Johnson applied for Emergency Use Authorisation for its single-dose Covid vaccine in India. The US drug major claims that its vaccine, in clinical trials, proved to be 85 per cent effective in preventing severe disease. The vaccine also showed protection against the Delta variant and other emerging strains.
